Physician profile
Padmini Varadarajan
NPI 1255379301
$1,370.97
in general payments reported to CMS, 2019-2025
11 companies · $289 in 2025
The $289 reported for 2025 was more than what a typical Adult Congenital Heart Disease provider received nationally (typical 2025 total: $272).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $248 · 2020: $15.62 · 2021: $327 · 2022: $114 · 2024: $377 · 2025: $289.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $666.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $666.41 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abiomed | $413.33 | 2024-2025 | Impella |
| Edwards Lifesciences Corporation | $249.61 | 2021-2024 | Sapien 3 Ultra Resilia |
| Artivion, INC. | $247.96 | 2019 | |
| Abbott Laboratories | $148.96 | 2021 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $99.19 | 2022-2025 | Lifevest |
| Bridgebio Pharma, INC. | $64.16 | 2025 | Attruby |
| Pfizer INC. | $50.95 | 2025 | |
| Irhythm Technologies, INC. | $39.35 | 2021-2022 | |
| Medtronic, INC. | $23.12 | 2021 | |
| Novartis Pharmaceuticals Corporation | $18.72 | 2022 | |
| E.R. Squibb & Sons, L.L.C. | $15.62 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Padmini Varadarajan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.